Pfizer Receives Authorization From Health Authority for Its 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
The health department has approved the pfizer 20-valent pneumococcal conjugate vaccine for infants and children.
Pfizer (PFE.US) announced that the Hong Kong Department of Health has approved the 20-valent pneumococcal conjugate vaccine for active immunization in infants, children, and adolescents aged 6 weeks to under 18 years, to combat invasive diseases, pneumonia, and acute otitis media caused by Streptococcus pneumoniae. Previously, this vaccine was approved for adults aged 18 and older. The 20-valent pneumococcal conjugate vaccine adds seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) on the basis of the previously approved 13-valent pneumococcal conjugate vaccine, and these serotypes may be associated with antibiotic resistance and increased disease severity.
Pfizer Options Spot-On: On December 2nd, 127.37K Contracts Were Traded, With 3.39 Million Open Interest
On December 2nd ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 127.37K options for the day, of which put options accounted for 49.81% of the total transactions, and
10 Health Care Stocks With Whale Alerts In Today's Session
Zacks.com Featured Highlights Tyson Foods, AXIS Capital, Pfizer and General Motors
Pfizer Options Spot-On: On November 29th, 93,129 Contracts Were Traded, With 3.39 Million Open Interest
On November 29th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 93,129 options for the day, of which put options accounted for 30.47% of the total transactions, and